Robotic Surgery Leader Intuitive Surgical Stock Drops Despite Strong Revenue Beat

2026-10-21 companies

Sunnyvale, Wednesday, 21 October 2026.
Despite beating quarterly revenue expectations with $3.05 billion, Intuitive Surgical saw its stock fall as a narrowed procedure growth outlook and a $450 million legal charge spooked investors.

Market Reaction to Earnings Report

Intuitive Surgical (NASDAQ: ISRG) experienced a significant decline in stock value following the release of its third-quarter financial results on October 20, 2026 [2]. Shares fell approximately 7% in after-hours trading despite the company beating quarterly revenue expectations [1]. Some market analyses indicated a drop of up to 12.7% as investors reacted to the news [5]. The robotic surgery pioneer posted adjusted earnings per share of $3.00, beating the analyst consensus of $2.65 by $0.35 [6]. This positive earnings surprise was overshadowed by concerns regarding future growth momentum [1]. The company is headquartered in Sunnyvale, California, and has been a leader in robotic-assisted surgical solutions since 1995 [7].

Revenue and Earnings Performance

For the quarter ended September 30, 2026, Intuitive Surgical generated $3.05 billion in revenue, representing a 22% increase year over year [2]. This growth rate is derived from the previous year’s third-quarter revenue of $2.51 billion, calculated as 21.514 [2]. Non-GAAP earnings per share increased 25% to $3, surpassing the estimated $2.64, which represents a beat of 13.636 percent [4]. However, GAAP net income was reported at $523 million, down from $704 million in the same period of 2025 [2]. This decrease was primarily affected by a $450 million pre-tax charge related to an antitrust class action settlement [2]. The settlement remains subject to preliminary and final Court approval [2].

Guidance and Future Outlook

Investor sentiment turned negative after management narrowed its full-year procedure growth guidance [1]. The company narrowed its forecast for da Vinci procedure growth to 14%-15%, compared with 13.5%-15.5% previously [1]. Management noted that additional tariffs could have a material adverse impact on financial results if currently active tariffs remain in place through the end of 2026 [2]. Intuitive expects instruments and accessories revenue per procedure to decline roughly 3% to 5% once pricing actions are fully implemented [3]. These pricing changes aim to encourage broader adoption of robotic surgery despite near-term revenue pressure [3]. The company’s financial guidance assumes currently active tariffs remain in place through the end of 2026 [2].

Operational Metrics and System Placements

During the third quarter, the group placed 546 da Vinci systems, which is 28% more than a year earlier [1]. This included 315 units of the new da Vinci 5 platform [1]. The installed base now stands at 12,094 robots, reflecting a 12% year-over-year increase [4]. Procedures increased 14% for da Vinci and 31% for Ion, driving recurring instrument and accessory revenue [1]. Chief Executive Officer Dave Rosa noted that customers performed more than 10,000 procedures per day on average during the period [2]. Investors can review further details from the earnings conference call scheduled for 1:30 p.m. PDT on October 20, 2026 [8].

Sources

Earnings Report Robotic Surgery